A Phase I Randomized Placebo-controlled Double-blind Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QuantiFERON-TB Gold (+) and QuantiFERON-TB Gold (-) Adults Without Evidence of Tuberculosis.
Phase of Trial: Phase I
Latest Information Update: 26 Mar 2016
At a glance
- Drugs Tuberculosis vaccine (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors Aeras; Crucell
- 10 Jun 2017 Biomarkers information updated
- 26 Mar 2016 Results (n=20) published in the Vaccine.
- 02 May 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.